AUG 27, 2019 9:00 AM PDT

Akoya Biosciences Webinar Series: Comprehensive Meta-analysis of Biomarker Technologies for Predictive Response of PD-1/PD-L1 Checkpoint Therapies

Sponsored by: Akoya Biosciences
C.E. Credits: P.A.C.E. CE Florida CE
Speakers
  • Vice President, Translational and Scientific Affairs, Akoya Biosciences
    Biography
      Dr. Cliff Hoyt is the Vice President of Translational and Scientific Affairs, having joined Akoya Bio through the acquisition of the Phenoptics business from Perkin-Elmer. Previously, Cliff was co-founder and CTO of CRI, Inc., acquired by PerkinElmer in 2011. Since then, as Oncology Fellow, Cliff lead development of multiplexed staining methods (Opal), built the contract research business, partnered with pharma and academia to understand translational research and clinical needs and to advance adoption of multiplexed immunofluorescence methods, and worked with PKI business leaders to develop an oncology translational strategy. Cliff has been Principal Investigator on NIH SBIR grants, received his BA in Physics from Williams College in 1983 and MS in Mechanical Engineering from MIT in 1987, and is named inventor on over 20 patents.
    • MD/PhD candidate, John Hopkins University School of Medicine
      Biography
        Steve Lu is currently enrolled in the Medical Scientist Training Program (MD/PhD) at Johns Hopkins University School of Medicine where I am working on my PhD degree in Cellular and Molecular Medicine. Graduated from college from University of Texas at Austin with degrees in Biology and Biochemistry where I researched on DNA repair and carcinogenesis.

        Mr. Lu's current research focuses on cancer genetics and immunotherapies in the context of skin cancers and mismatch repair-deficient tumors. More specifically, my research uses genomics and multi parametric assays to understand the mechanisms that tumors use to evade the immune system. The goal is to lead to improved patient selection for therapies and to identify additional pathways that can be targeted.

      Abstract
      DATE:  August 27, 2019 
      TIME:  9:00am PDT, 12:00pm EDT
       
      Immunotherapies targeting the PD-1/PD-L1 interaction have proven remarkably effective for treating cancer in some patients. There has now been considerable focus into the sensitivity and specificity measures of the technologies used to predict clinical response and aid in better patient selection. Recently, researchers at Johns Hopkins School of Medicine published a comprehensive comparison in JAMA Oncology to determine the relative accuracy of these biomarker assays including PD-L1 immunohistochemistry (IHC), multiplexed immunofluoresence (mIF) and genomic approaches including tumor mutational burden (TMB) and gene expression profiling (GEP). Steve Lu, of Johns Hopkins School of Medicine will present the study results demonstrating the improved predictive value of multiplexed IHC/IF methods compared to other modalities. The review compared results of over 8000 patients from over 45 published studies detailing the treatment selection across multiple types of lung, bladder, skin, and gastric amongst other cancers. Statistical analysis of the different methods suggest multiplexed IHC/IF biomarker strategies are associated with improved predictive performance over PD-L1 IHC, TMB or GEP approaches alone.
       
      Learning Objectives:
      • Comparative predictive metrics across multiple biomarker technologies for predicting PD-1/PD-L1 therapies
      • Importance of quantitative protein measurements of immune cell subsets and impact of spatial arrangements in disease states
      • Latest advances in multiplexed immunofluorescent methods for robust, high throughput clinical research.
       
       
      Webinars will be available for unlimited on-demand viewing after live event.

      LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

      Show Resources
      You May Also Like
      MAY 11, 2021 10:00 AM PDT
      C.E. CREDITS
      MAY 11, 2021 10:00 AM PDT
      Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
      JUN 09, 2021 7:00 AM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      JUN 09, 2021 7:00 AM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
      DEC 02, 2020 8:00 AM PST
      C.E. CREDITS
      DEC 02, 2020 8:00 AM PST
      DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
      NOV 16, 2020 8:00 AM PST
      C.E. CREDITS
      NOV 16, 2020 8:00 AM PST
      Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
      NOV 18, 2020 8:00 AM PST
      C.E. CREDITS
      NOV 18, 2020 8:00 AM PST
      DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
      APR 01, 2021 8:00 AM PDT
      C.E. CREDITS
      APR 01, 2021 8:00 AM PDT
      Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
      AUG 27, 2019 9:00 AM PDT

      Akoya Biosciences Webinar Series: Comprehensive Meta-analysis of Biomarker Technologies for Predictive Response of PD-1/PD-L1 Checkpoint Therapies

      Sponsored by: Akoya Biosciences
      C.E. Credits: P.A.C.E. CE Florida CE

      Specialty

      Cancer Research

      Immunology

      Molecular Biology

      Biomarkers

      Cancer Diagnostics

      Cell Biology

      Biotechnology

      Cancer Therapeutics

      Oncology

      Molecular Diagnostics

      Clinical Research

      Genetics

      Clinical Diagnostics

      Cell Culture

      Genomics

      Geography

      North America60%

      Europe21%

      Asia12%

      Africa3%

      South America1%

      Oceania1%

      Registration Source

      Website Visitors56%

      Email Promotions33%

      WAVE Newsletter Promotion6%

      Trending Newsletter Promotion3%

      Social Media Promotions1%

      Client/Sponsor Promotions1%

      Other2%

      Job Title

      Scientist16%

      Research Scientist15%

      Executive15%

      Educator/Faculty9%

      Facility/Department Manager9%

      Student8%

      Lab Management6%

      Medical Laboratory Technician5%

      Post Doc4%

      Medical Doctor/Specialist4%

      Pathologist3%

      Marketing/Sales2%

      Clinical Laboratory Scientist2%

      Consultant1%

      Organization

      Academic Institution24%

      Biotech Company18%

      Hospital10%

      Pharmaceutical Company8%

      Life Science Company5%

      Research Institute4%

      Clinical Laboratory4%

      Consultant3%

      Medical School3%

      Contract Research Organization (Cro)3%

      Industrial Company2%

      Medical Device Company2%

      Medical Center2%

      Government2%

      Other2%


      Show Resources
      Loading Comments...
      Show Resources